The 10 latest articles on Cell & Gene Therapies come from 8 sources, published between Nov 4 and Nov 13. Most come from MarketScreener (2) and Securities.io (2).
Organizations: Beam (3), BLA (3), U.S. Food and Drug Administration (3), FDA (3), American Society of Hematology (3), SCD (2)
Places: New Orleans (3), U.S. (2), United States (2), Calif. (2), MD (2)
Beam Therapeutics said Tuesday its Beacon phase 1/2 study of ristoglogene autogetemcel, or risto-cel, in patients with sickle cell disease met its primary efficacy and safety endpoints at a... Biotechnology & Medical Research Beam Therapeutics Says Risto-Cel Meets Primary Endpoints in Sickle Cell…
Published on 11/10/2026 at 07:00 am EST Beam Therapeutics Inc. announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). Risto-cel is an investigational one-time, autologous cell…
November 4, 2026 at 9:00 AM EST PDF Version BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission…
Biotechnology Beam Sickle Cell Therapy Meets Pivotal Goals Ahead of Planned BLA Published November 10, 2026 By Anika Patel Genomics & Synthetic Biology, AI Research Agent Add Securities.io to your preferred sources on Google Beam Therapeutics (BEAM ) announced on November 10, 2026 that ristoglogene…
This is a paid press release. Contact the press release distributor directly with any inquiries. Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Nula-cel, a Gene-Corrected Stem Cell Therapy for Sickle Cell Disease Kamau Therapeutics Thu, November…
By: Tempest Therapeutics via GlobeNewswire September 15, 2026 at 16:05 PM EDT ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. -Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in…
Biotechnology IASO Bio Wins China IND Approval for IASO208 CAR-T Therapy Published November 11, 2026 By Louis Mbaye Pharma & AI Drug Discovery, AI Research Agent Add Securities.io to your preferred sources on Google IASO Bio announced on November 11, 2026, that China’s National Medical…
Video by Stefan Muehleis / Fred Hutch News Service Fred Hutch turns 50! Take a look back at half a century of leading-edge research and compassionate care. CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how…
CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
An article joins this feed when it matches these terms. Each one is also a search of its own.